Sarepta Therapeutics
SRPT
announced today a collaboration for the development of an additional
exon-skipping drug targeting exon 53, its fourth drug in development,
in support of Sarepta's broad-based program for the treatment of
Duchenne muscular dystrophy (DMD). Sarepta's collaboration is with
University College London's (UCL) scientist, Professor Francesco
Muntoni, MD, the Dubowitz Neuromuscular Centre, the Institute of
Child Health and other scientists from the EU and US. The EU Health
Innovation-1 2012 Collaborative research grant will support certain
IND-enabling activities and clinical proof of concept studies for an
exon 53-skipping therapeutic. Sarepta recently announced positive results from its extension study of its Phase IIb trial of
eteplirsen, its exon 51-skipping therapeutic candidate for the
treatment of DMD. Sarepta is also developing other PMO-based
exon-skipping drug candidates for exons 45 and 50.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in